Argon laser ablation of malignant ventricular tachycardia associated with coronary artery disease.
The long-term clinical efficacy and safety of intraoperative mapping-guided argon laser ablation alone or in conjunction with standard surgical methods were assessed in 20 consecutive patients with refractory sustained ventricular tachycardia (VT) or ventricular fibrillation. A 15-W argon ion gas laser was used and pulsed laser energy was delivered through a fiberoptic catheter delivery system. Pre- and intraoperative mapping was used to localize the arrhythmogenic tissue. Postoperative clinical, ambulatory electrocardiographic and electrophysiologic evaluations were performed before discharge and at 1 year of follow-up. Thirty-eight VT morphologies were mapped and ablated with laser energy alone (82%), combined laser ablation and mechanical resection (13%) or mechanical resection alone (5%). Concomitant coronary artery bypass surgery was performed in 15 patients and in 1 patient it was performed with mitral value replacement. Postoperative 30-day mortality was 5%. One patient (5%) required postoperative antiarrhythmic drug therapy, and all survivors had suppression of inducible sustained VT at discharge. Mean left ventricular ejection fraction increased from 34 +/- 12% preoperatively to 41 +/- 13% postoperatively (p = 0.001). Efficacy rates for ablation of VT sites associated with anterior myocardial infarction and inferior or posterior myocardial infarction were comparable (100 vs 96%, respectively, p greater than 0.2). At 1-year follow-up no sudden deaths had occurred and total survival rate was 90%. Intraoperative pulsed argon laser ablation alone or in conjunction with standard surgical techniques improves the efficacy of surgical ablation procedures for VT or ventricular fibrillation and reduces the need for additional postoperative antiarrhythmic drug or device therapy.